Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib

Clin Chem. 2004 Jul;50(7):1233-7. doi: 10.1373/clinchem.2004.034801.

Authors

Julie A E Irving¹, Stephen O'Brien, Anne L Lennard, Lynne Minto, Feng Lin, Andrew G Hall

Affiliation

¹ Leukaemia Research Fund Molecular Pharmacology Laboratory, School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle, UK. j.a.e.irving@ncl.ac.uk

PMID: 15229152
DOI: 10.1373/clinchem.2004.034801

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Chromatography, High Pressure Liquid / methods
Drug Resistance, Neoplasm
Exons
Fusion Proteins, bcr-abl
Genes, abl*
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
Mutation
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / genetics*
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases
Fusion Proteins, bcr-abl